The patient's health – is at the stake

9353 просмотров

The leading Swiss company is in favor of ethical promotion of biological products at the pharmaceutical market of Kazakhstan

Questions promotion of biological products at the pharmaceutical market of Kazakhstan were discussed at the site of NCE RK by Deputy Chairman of the National Chamber of Entrepreneurs of Kazakhstan "Atameken" Yuliya Yakupbaeva and CEO of LLP "Kazakhstan Roche" George Ramishvili, with the participation of Extraordinary and Plenipotentiary Ambassador of Switzerland to Kazakhstan Mauro Reina.

The Company Roche – is one of the leading producers of biotech medicines in oncology, virology, rheumatology and transplantation, it has offices in 150 countries. The company mainly develops innovative drugs for the treatment of socially significant diseases, including expensive biologic drugs (targeted), based on a personalized approach to patient care.

It was noted that global trends in the pharmaceutical industry set a difficult task for Kazakhstani pharmaceutical market to ensure quality supply of patients with costly biologic drugs in a cost savings time, while maintaining a balance between the interests of industry and public health objectives.

As part of the development of Kazakhstan's pharmaceutical industry, some domestic manufacturers intend to open production lines for the production of biosimilars, i.e. products similar (similar) to the original biological product in terms of quality, biological activity, efficacy and safety. As a rule, the price of biosimilars is relatively lower than that of the original biological products.

It is worth noting that in recent years in the world especially the use of biological agents, related to the possibility of evoking of different individual immune responses in the human body that can’t be recorded during clinical trials for registration, and become a topic of debate between the producers of original biologicals and biosimilars.

Issues of supply of patients with quality and secure biological agents are possible to ensure, provided that the quality of both foreign and domestic production, clinical trials, registration procedures, procurement, medical practice, the system of pharmaceutical control of products on the market of the EAEU are uniform.

General director of "Roche Kazakhstan" Giorgi Ramishvili, informed the participants of the meeting with the peculiarities of the use of biological agents, and noted the importance of the ethical promotion of drugs on the market of Kazakhstan.

Deputy Chairman of NCE RK "Atameken" Yuliya Yakupbaeva noted the need for the development of e-healthcare for the proper monitoring of medical appointments, registration and purchase of biologicals mechanisms, and proposed to suggest the best options to address the above issues in the consideration of draft legal acts, regulating the provision of medicines within the guaranteed free medical care and mandatory social health insurance.

The parties also plan to prepare jointly a reasoned basis in relation to the introduction of the concept of "interchangeability of medicines" during registration of products at the common pharmaceutical market of EAEU, given the acuteness of the issue in the discussions between the Member States of EAEU.